Human recombinant activated protein C vs placebo
Serious adverse events (adult and paediatric patients) · patients with severe sepsis or septic shock
Human recombinant activated protein C showed no clear difference in serious adverse events (adult and paediatric patients) compared with placebo (moderate certainty).
1 finding from 1 review
- Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients 2012 · Cochrane Headline outcomes onlyRR 1.04 [0.92, 1.18]5 studies · 6636 participantsModerate